BIOMAT Database Logo BIOMAT Database Logo

Tumor necrosis factor alpha in ulcerative colitis and diverticular disease associated colitis. 2007

C Hassan, and A Zullo, and V De Francesco, and S M A Campo, and S Morini, and C Panella, and E Ierardi
Ospedale Nuovo Regina Margherita, Gastroenterologia ed Endoscopia Digestiva, Via Morosini 30, 00153, Roma, Italia. cesareh@hotmail.com

Conventional treatment of moderate-severe ulcerative colitis (UC) has resulted in only a limited therapeutic benefit. Advancing knowledge of UC pathogenesis and recent advances in biotechnology have led to the development of biological agents that selectively target individual inflammatory pathways. In particular, the role of tumor necrosis factor alpha (TNF-alpha) in UC pathogenesis has been clarified by serological and immunohistochemical studies in humans and by experimental models. Clinical efficacy of anti-TNF-alpha therapy with infliximab has been assessed in two large controlled trials, showing a good compromise between therapeutic gain and safety. The aim of this review is to provide an insight into the role of TNF-alpha and anti-TNF-alpha therapy in patients with UC and diverticular disease associated colitis.

UI MeSH Term Description Entries
D003092 Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER. Colitides
D003093 Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN. Colitis Gravis,Idiopathic Proctocolitis,Inflammatory Bowel Disease, Ulcerative Colitis Type,Ulcerative Colitis
D004240 Diverticulum A pouch or sac developed from a tubular or saccular organ, such as the GASTROINTESTINAL TRACT. Diverticulosis,Diverticula
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha

Related Publications

C Hassan, and A Zullo, and V De Francesco, and S M A Campo, and S Morini, and C Panella, and E Ierardi
Tumor necrosis factor-alpha inhibitor associated ulcerative colitis.
March 2007, The American journal of the medical sciences,
C Hassan, and A Zullo, and V De Francesco, and S M A Campo, and S Morini, and C Panella, and E Ierardi
Tumor necrosis factor-alpha polymorphisms in ulcerative colitis-associated colorectal cancer.
February 2008, The American journal of gastroenterology,
C Hassan, and A Zullo, and V De Francesco, and S M A Campo, and S Morini, and C Panella, and E Ierardi
A case of diverticular colitis with lesions resembling ulcerative colitis and correlation of tumor necrosis factor-alpha staining with clinical manifestations.
December 2015, Clinical journal of gastroenterology,
C Hassan, and A Zullo, and V De Francesco, and S M A Campo, and S Morini, and C Panella, and E Ierardi
Tumor necrosis factor alpha and colitis-associated colon cancer.
June 2008, The New England journal of medicine,
C Hassan, and A Zullo, and V De Francesco, and S M A Campo, and S Morini, and C Panella, and E Ierardi
Expression of matrix metalloproteinase-1 and tumor necrosis factor-alpha in ulcerative colitis.
November 2007, World journal of gastroenterology,
C Hassan, and A Zullo, and V De Francesco, and S M A Campo, and S Morini, and C Panella, and E Ierardi
Two-year delay in ulcerative colitis diagnosis is associated with anti-tumor necrosis factor alpha use.
February 2019, World journal of gastroenterology,
C Hassan, and A Zullo, and V De Francesco, and S M A Campo, and S Morini, and C Panella, and E Ierardi
[Expression of tumor necrosis factor-alpha and nuclear factor-kappa B in childhood ulcerative colitis].
October 2003, Zhonghua er ke za zhi = Chinese journal of pediatrics,
C Hassan, and A Zullo, and V De Francesco, and S M A Campo, and S Morini, and C Panella, and E Ierardi
Anti-tumor necrosis factor therapy for ulcerative colitis.
September 2005, Gastroenterology,
C Hassan, and A Zullo, and V De Francesco, and S M A Campo, and S Morini, and C Panella, and E Ierardi
Anti-tumor necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease.
November 2018, Gastroenterologia y hepatologia,
C Hassan, and A Zullo, and V De Francesco, and S M A Campo, and S Morini, and C Panella, and E Ierardi
[A meta analysis of tumor necrosis factor alpha blockers therapy for ulcerative colitis].
June 2011, Zhonghua nei ke za zhi,
Copied contents to your clipboard!